In the Matter of Certain Insulin Delivery Devices Including Cartridges Having Adaptor Tops and Components Thereof; Notice of a Commission Determination Not To Review an Initial Determination Terminating the Investigation in Its Entirety Based Upon Withdrawal of the Complaint, 8790 [E7-3393]
Download as PDF
8790
Federal Register / Vol. 72, No. 38 / Tuesday, February 27, 2007 / Notices
INTERNATIONAL TRADE
COMMISSION
[Inv. No. 337–TA–572]
In the Matter of Certain Insulin Delivery
Devices Including Cartridges Having
Adaptor Tops and Components
Thereof; Notice of a Commission
Determination Not To Review an Initial
Determination Terminating the
Investigation in Its Entirety Based
Upon Withdrawal of the Complaint
U.S. International Trade
Commission.
ACTION: Notice.
cprice-sewell on PROD1PC62 with NOTICES
AGENCY:
SUMMARY: Notice is hereby given that
the U.S. International Trade
Commission has determined not to
review an initial determination (‘‘ID’’) of
the presiding administrative law judge
(‘‘ALJ’’) in the above-captioned
investigation terminating the abovecaptioned investigation as to all
respondents based on withdrawal of the
complaint.
FOR FURTHER INFORMATION CONTACT:
Michael K. Haldenstein, Office of the
General Counsel, U.S. International
Trade Commission, 500 E Street, SW.,
Washington, DC 20436, telephone (202)
205–3041. Copies of the public version
of the ALJ’s ID and all other
nonconfidential documents filed in
connection with this investigation are or
will be available for inspection during
official business hours (8:45 a.m. to 5:15
p.m.) in the Office of the Secretary, U.S.
International Trade Commission, 500 E
Street, SW., Washington, DC 20436,
telephone 202–205–2000. General
information concerning the Commission
may also be obtained by accessing its
Internet server (https://www.usitc.gov).
The public record for this investigation
may be viewed on the Commission’s
electronic docket (EDIS) at https://
edis.usitc.gov. Hearing-impaired
persons are advised that information on
this matter can be obtained by
contacting the Commission’s TDD
terminal on 202–205–1810.
SUPPLEMENTARY INFORMATION: The
Commission instituted this investigation
on June 9, 2006, based on a complaint
filed by Novo Nordisk A/S of Denmark,
Novo Nordisk Inc., of New Jersey and
Novo Nordisk Pharmaceuticals
Industries, Inc. of North Carolina. 71 FR
33484 (June 9, 2006). The complaint, as
supplemented, alleged violations of
section 337 in the importation into the
United States, the sale for importation,
and the sale within the United States
after importation of certain insulin
delivery devices, including cartridges
having adaptor tops, and components
VerDate Aug<31>2005
15:22 Feb 26, 2007
Jkt 211001
thereof, by reason of infringement of
claims 1–3, 5–7, 11, 18, and 19 of U.S.
Patent 5,693,027. The complaint further
alleged that an industry in the United
States exists or is in the process of being
established as required by subsection
(a)(2) of section 337. The complainants
requested that the Commission issue a
limited exclusion order and cease and
desist order. The Commission named
three companies as respondents: SanofiAventis Deutschland GmbH of
Germany, Sanofi-Aventis of France, and
Aventis Pharmaceuticals, Inc. of New
Jersey. The ALJ set August 23, 2007 as
the target date for completion of the
investigation.
On October 5, 2006, complainants
filed a motion to withdraw the
complaint and terminate the
investigation as to all parties. The three
respondents filed a response to the
motion on October 13, 2006, arguing
that while they did not oppose
termination of the investigation,
sanctions and termination with
prejudice were appropriate. The
Commission investigative attorney
supported the motion for termination of
the investigation and opposed
imposition of sanctions and termination
of the investigation with prejudice.
On January 29, 2007, the ALJ issued
the subject ID (Order No. 6) granting
complainants’ motion to terminate the
investigation without prejudice based
upon withdrawal of the complaint. No
petitions for review of the ID were filed.
The Commission has determined not to
review this ID.
This action is taken under the
authority of section 337 of the Tariff Act
of 1930, as amended, 19 U.S.C. 1337,
and Commission rules 210.21 and
210.42, 19 CFR 210.21 and 210.42.
By order of the Commission.
Issued: February 21, 2007.
Marilyn R. Abbott,
Secretary to the Commission.
[FR Doc. E7–3393 Filed 2–26–07; 8:45 am]
BILLING CODE 7020–02–P
INTERNATIONAL TRADE
COMMISSION
[Inv. No. 337–TA–594]
In the Matter of Certain Lighting
Products, Components Thereof, and
Products Containing the Same; Notice
of Investigation
U.S. International Trade
Commission.
ACTION: Institution of investigation
pursuant to 19 U.S.C. 1337.
AGENCY:
PO 00000
Frm 00113
Fmt 4703
Sfmt 4703
SUMMARY: Notice is hereby given that a
complaint was filed with the U.S.
International Trade Commission on
January 23, 2007, under section 337 of
the Tariff Act of 1930, as amended, 19
U.S.C. 1337, on behalf of Cooper
Lighting, Inc. of Peachtree City, GA. A
supplement to the complaint was filed
on February 9, 2007. The complaint, as
supplemented, alleges violations of
section 337 in the importation into the
United States, the sale for importation,
and the sale within the United States
after importation of certain lighting
products, components thereof, and
products containing the same by reason
of infringement of certain claims of U.S.
Patent Nos. 6,082,878 and 5,662,413.
The complaint further alleges that an
industry in the United States exists as
required by subsection (a)(2) of section
337.
The complainant requests that the
Commission institute an investigation
and, after the investigation, issue a
permanent exclusion order and a
permanent cease and desist order.
ADDRESSES: The complaint and
supplement, except for any confidential
information contained therein, are
available for inspection during official
business hours (8:45 a.m. to 5:15 p.m.)
in the Office of the Secretary, U.S.
International Trade Commission, 500 E
Street, SW., Room 112, Washington, DC
20436, telephone 202–205–2000.
Hearing impaired individuals are
advised that information on this matter
can be obtained by contacting the
Commission’s TDD terminal on 202–
205–1810. Persons with mobility
impairments who will need special
assistance in gaining access to the
Commission should contact the Office
of the Secretary at 202–205–2000.
General information concerning the
Commission may also be obtained by
accessing its Internet server at https://
www.usitc.gov. The public record for
this investigation may be viewed on the
Commission’s electronic docket (EDIS)
at https://edis.usitc.gov.
FOR FURTHER INFORMATION CONTACT:
Bryan F. Moore, Esq., Office of Unfair
Import Investigations, U.S. International
Trade Commission, telephone (202)
205–2767.
Authority: The authority for
institution of this investigation is
contained in section 337 of the Tariff
Act of 1930, as amended, and in section
210.10 of the Commission’s Rules of
Practice and Procedure, 19 CFR 210.10
(2006).
Scope of Investigation: Having
considered the complaint, the U.S.
International Trade Commission, on
February 21, 2007, ordered that—
E:\FR\FM\27FEN1.SGM
27FEN1
Agencies
[Federal Register Volume 72, Number 38 (Tuesday, February 27, 2007)]
[Notices]
[Page 8790]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-3393]
[[Page 8790]]
-----------------------------------------------------------------------
INTERNATIONAL TRADE COMMISSION
[Inv. No. 337-TA-572]
In the Matter of Certain Insulin Delivery Devices Including
Cartridges Having Adaptor Tops and Components Thereof; Notice of a
Commission Determination Not To Review an Initial Determination
Terminating the Investigation in Its Entirety Based Upon Withdrawal of
the Complaint
AGENCY: U.S. International Trade Commission.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the U.S. International Trade
Commission has determined not to review an initial determination
(``ID'') of the presiding administrative law judge (``ALJ'') in the
above-captioned investigation terminating the above-captioned
investigation as to all respondents based on withdrawal of the
complaint.
FOR FURTHER INFORMATION CONTACT: Michael K. Haldenstein, Office of the
General Counsel, U.S. International Trade Commission, 500 E Street,
SW., Washington, DC 20436, telephone (202) 205-3041. Copies of the
public version of the ALJ's ID and all other nonconfidential documents
filed in connection with this investigation are or will be available
for inspection during official business hours (8:45 a.m. to 5:15 p.m.)
in the Office of the Secretary, U.S. International Trade Commission,
500 E Street, SW., Washington, DC 20436, telephone 202-205-2000.
General information concerning the Commission may also be obtained by
accessing its Internet server (https://www.usitc.gov). The public record
for this investigation may be viewed on the Commission's electronic
docket (EDIS) at https://edis.usitc.gov. Hearing-impaired persons are
advised that information on this matter can be obtained by contacting
the Commission's TDD terminal on 202-205-1810.
SUPPLEMENTARY INFORMATION: The Commission instituted this investigation
on June 9, 2006, based on a complaint filed by Novo Nordisk A/S of
Denmark, Novo Nordisk Inc., of New Jersey and Novo Nordisk
Pharmaceuticals Industries, Inc. of North Carolina. 71 FR 33484 (June
9, 2006). The complaint, as supplemented, alleged violations of section
337 in the importation into the United States, the sale for
importation, and the sale within the United States after importation of
certain insulin delivery devices, including cartridges having adaptor
tops, and components thereof, by reason of infringement of claims 1-3,
5-7, 11, 18, and 19 of U.S. Patent 5,693,027. The complaint further
alleged that an industry in the United States exists or is in the
process of being established as required by subsection (a)(2) of
section 337. The complainants requested that the Commission issue a
limited exclusion order and cease and desist order. The Commission
named three companies as respondents: Sanofi-Aventis Deutschland GmbH
of Germany, Sanofi-Aventis of France, and Aventis Pharmaceuticals, Inc.
of New Jersey. The ALJ set August 23, 2007 as the target date for
completion of the investigation.
On October 5, 2006, complainants filed a motion to withdraw the
complaint and terminate the investigation as to all parties. The three
respondents filed a response to the motion on October 13, 2006, arguing
that while they did not oppose termination of the investigation,
sanctions and termination with prejudice were appropriate. The
Commission investigative attorney supported the motion for termination
of the investigation and opposed imposition of sanctions and
termination of the investigation with prejudice.
On January 29, 2007, the ALJ issued the subject ID (Order No. 6)
granting complainants' motion to terminate the investigation without
prejudice based upon withdrawal of the complaint. No petitions for
review of the ID were filed. The Commission has determined not to
review this ID.
This action is taken under the authority of section 337 of the
Tariff Act of 1930, as amended, 19 U.S.C. 1337, and Commission rules
210.21 and 210.42, 19 CFR 210.21 and 210.42.
By order of the Commission.
Issued: February 21, 2007.
Marilyn R. Abbott,
Secretary to the Commission.
[FR Doc. E7-3393 Filed 2-26-07; 8:45 am]
BILLING CODE 7020-02-P